Literature DB >> 29282798

Estimating a cost-effectiveness threshold for the Spanish NHS.

Laura Vallejo-Torres1,2,3, Borja García-Lorenzo1,4, Pedro Serrano-Aguilar1,3,5.   

Abstract

The cost of generating a quality-adjusted life year (QALY) within a National Health Service provides an approximation of the average opportunity cost of funding decisions. This information can be used to inform a cost-effectiveness threshold. The aim of this paper is to estimate the cost per QALY at the Spanish National Health Service. We exploit variation across 17 regional health services and the exogenous changes in expenditure that took place as a consequence of the economic crisis over 5 years of data. We conduct fixed effect models and use an instrumental variable approach to test for potential remaining endogeneity. Our results show that health expenditure has a positive and significant effect on population health, with an average spending elasticity of 0.07. This translates into a cost per QALY of between 22,000€ and 25,000€. These values are below the cost-effectiveness threshold figure of 30,000€ commonly cited in Spain.
Copyright © 2017 John Wiley & Sons, Ltd.

Keywords:  QALY; cost-effectiveness; health care spending; threshold

Mesh:

Year:  2017        PMID: 29282798     DOI: 10.1002/hec.3633

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  61 in total

1.  Modifying NICE's Approach to Equity Weighting.

Authors:  Mike Paulden; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2021-01-31       Impact factor: 4.981

2.  Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?

Authors:  Jorge Mestre-Ferrandiz; Néboa Zozaya; Bleric Alcalá; Álvaro Hidalgo-Vega
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

3.  When is it too expensive? Cost-effectiveness thresholds and health care decision-making.

Authors:  Werner Brouwer; Pieter van Baal; Job van Exel; Matthijs Versteegh
Journal:  Eur J Health Econ       Date:  2019-03

4.  How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13.

Authors:  Stephen Martin; James Lomas; Karl Claxton; Francesco Longo
Journal:  Appl Health Econ Health Policy       Date:  2021-07-21       Impact factor: 2.561

5.  Reply to letter from Alvarez et al.

Authors:  Jesús Ruiz-Aragón; Ray Gani; Sergio Márquez; Piedad Alvarez
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

6.  The societal monetary value of a QALY associated with EQ-5D-3L health gains.

Authors:  Laura Vallejo-Torres; Borja García-Lorenzo; Oliver Rivero-Arias; José Luis Pinto-Prades
Journal:  Eur J Health Econ       Date:  2019-11-28

7.  Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain.

Authors:  Jesús Ruiz-Aragón; Ray Gani; Sergio Márquez; Piedad Alvarez
Journal:  Hum Vaccin Immunother       Date:  2020-02-10       Impact factor: 3.452

8.  Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries.

Authors:  James Lomas; Karl Claxton; Jessica Ochalek
Journal:  Health Policy Plan       Date:  2022-01-13       Impact factor: 3.344

Review 9.  Understanding cost-utility analysis studies in the trauma and orthopaedic surgery literature.

Authors:  Achi Kamaraj; Nikhil Agarwal; K T Matthew Seah; Wasim Khan
Journal:  EFORT Open Rev       Date:  2021-05-04

10.  Economic evaluation of process utility: elucidating preferences for a non-invasive procedure to treat restenosis.

Authors:  Maria V Aviles-Blanco
Journal:  Health Econ Rev       Date:  2021-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.